Astromech (co-founded with Harvard geneticist George Church) will quickly become a trillion-dollar enterprise by applying AI to predictive biology — leveraging massive time-series genomic data from de-extinction projects to predict pathogen mutation pa...

Astromech (co-founded with Harvard geneticist George Church) will quickly become a trillion-dollar enterprise by applying AI to predictive biology — leveraging massive time-series genomic data from de-extinction projects to predict pathogen mutation patterns and cancer resistance pathways, enabling preemptive drug development. | Astromech first pharma-partnership announcement

Key catalyst: Astromech first pharma-partnership announcement

Watch events: Astromech Series A funding; first preclinical validation

Astromech launched 2025-2026 via Colossal spin-out; Church academic credentials strong; trillion-dollar valuation aspirational.

No probability history yet. The first evidence will arrive via /api/intake or the daily milestone sweep / weekly LBP run.

Beneficiaries (20)

{
  "nia": false,
  "qty": "$1T valuation",
  "mode": "FORECAST",
  "role": "Cited-CEO",
  "context": "Lamm's second unicorn (distinct from Colossal de-extinction platform 245_xx series). Astromech applies evolutionary-pattern prediction to pharmaceutical R&D.",
  "to_year": 2035,
  "conv_cues": "specific valuation target; named scientific co-founder",
  "direction": "NUMERIC_TARGET",
  "from_year": 2028,
  "timeframe": "2028-2035",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -3,
      "source_id": null,
      "expected_date": "2029-04-29",
      "observed_date": null
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -2,
      "source_id": null,
      "expected_date": "2030-08-27",
      "observed_date": null
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q3 window check-in (75%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -1,
      "source_id": null,
      "expected_date": "2031-12-25",
      "observed_date": null
    },
    {
      "kind": "event",
      "label": "Astromech (co-founded with Harvard geneticist George Church) will quickly become a trillion-dollar enterprise by applying AI to predictive b",
      "status": "pending",
      "weight": 1,
      "ordinal": 0,
      "source_id": "AI_032",
      "expected_date": "2033-04-23",
      "observed_date": null
    }
  ],
  "repeat_eps": 1,
  "sub_domain": "Longevity",
  "affiliation": "Colossal Biosciences / Astromech",
  "attribution": "FIRST_PERSON",
  "granularity": "YEAR_RANGE",
  "source_refs": "61",
  "target_date": "2031-06-15T00:00:00",
  "display_date": "2033-04-23",
  "episode_date": "2026-04-21T00:00:00",
  "key_catalyst": "Astromech first pharma-partnership announcement",
  "parse_method": "YEAR_RANGE midpoint",
  "domain_bucket": "Biotech",
  "episode_title": "Forecasting the Inference Epoch: Expert AI Predictions & Macroeconomic Trajectories (2023-2026)",
  "flag_repeated": false,
  "in_5yr_window": false,
  "source_report": "AI Predictions Search Plan.md (2026-04-21)",
  "appears_in_eps": "AI-RPT",
  "futurist_phase": "Phase 3 (2029+)",
  "is_macro_claim": false,
  "total_mentions": 1,
  "priority_weight": 4,
  "ps_cluster_tags": [
    "C10"
  ],
  "report_evidence": "Anchor section: Astromech and Predictive Biology.",
  "active_end_month": "2035-12",
  "recent_statement": "LA Weekly profile 2026.",
  "watch_events_raw": "Astromech Series A funding; first preclinical validation",
  "months_from_today": 62,
  "probability_layer": "Lower (speculative)",
  "active_start_month": "2028-01",
  "december_dispersal": {
    "reason": "december_dispersal: domain=Biotech/Longevity → 09/2035",
    "new_date": "2035-09-30",
    "old_date": "2035-12-31",
    "applied_at": "2026-04-30T16:28:34.304992+00:00"
  },
  "flag_nia_bracketed": false,
  "track_record_grade": "B",
  "track_record_notes": "Lamm Colossal execution strong; Astromech valuation target speculative.",
  "contradicting_notes": "Pharma R&D productivity gains historically slower than AI-forecaster expectations; Recursion, Insitro, Xaira similar players competing.",
  "flag_near_term_2027": false,
  "flag_high_conviction": false,
  "milestones_phase2_at": "2026-05-01T21:26:03.399258+00:00",
  "milestones_derived_at": "2026-05-02T03:08:50.509654+00:00",
  "reference_class_match": {
    "top_n": [
      {
        "id": "agi_breakthrough_5y",
        "cosine": 0.4991
      }
    ],
    "margin": 0.4991,
    "best_id": "agi_breakthrough_5y",
    "decision": "below_threshold",
    "second_id": null,
    "threshold": 0.55,
    "computed_at": "2026-04-30T01:49:13.796883+00:00",
    "best_similarity": 0.4991,
    "margin_required": 0.05,
    "second_similarity": null
  },
  "validation_status_raw": "PENDING-UNCERTAIN",
  "